Affiliation:
1. Scientific Centre for Expert Evaluation of Medicinal Products
2. M.V. Lomonosov Moscow State University
Abstract
This work is a continuation of research on the use of X-ray diffraction analysis (XRD) for identification of medicines that exhibit polymorphism.The aim of the paper was to perform comparative XRD analysis of linezolid samples produced by different manufacturers.Materials and methods: the measurements were performed using an Empyrean X-ray powder diffraction system (PANalytical, Netherlands) with an X’Celerator linear solid-state detector using Ni-filtered CuKa radiation. The results were recorded at 1.5406 and 1.5444 А with the intensity ratio in the doublet of 2:1. The two-phase Rietveld refinement of the obtained diffractograms was used for the quantitative analysis.Results: the authors compared diffractograms of three commercial samples of linezolid. The revealed differences were analysed taking into consideration available literature on the polymorphic forms of linezolid. It was demonstrated that only forms II and IV should be considered as different polymorphs of linezolid.Conclusions: the study demonstrated that linezolid samples produced by different manufacturers could represent different polymorphs or mixtures thereof. The evaluation of linezolid quality by X-ray diffraction analysis requires the comparison of the obtained results with the diffractogram of the form IV reference standard. Relevant information should be provided by manufacturers in the product specification file.
Reference12 articles.
1. Kuzmin VS, Chernyshev VV, Luttseva AI. X-ray powder diffraction in quality control of medicines. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2018;(3):158-61 (In Russ.). https://doi.org/10.30895/1991-2919-2018-8-3-158-161
2. Efremen-kova OV, Belousov YuB. Linezolid — the first drug of a new class of antibacterial agents oxazolidinones. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2002;(2):2-11 (In Russ.)
3. Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ula-nowicz DA, Garmon SA, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39(3):673-9. https://doi.org/10.1021/jm9509556
4. Bergren MS. Linezolid — crystal form II. Patent No. US6559305B1; 2003.
5. Mohan Rao D, Krishna Reddy P. A novel crystalline form of linezolid. Patent No. W0/2005/035530; 2005.